Analysis of statistical indicators of the population of Saint Petersburg with malignant neoplasms of pancreas

2021 ◽  
Vol 23 (2) ◽  
pp. 155-164
Author(s):  
Vladislav E. Moiseenko ◽  
Alexander V. Pavlovsky ◽  
Dmitry A. Granov ◽  
Larisa V. Kochorova ◽  
Inna V. Dodonova ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Stage Iv ◽  
Malignant Neoplasms ◽  
Number Of Patients ◽  
Incidence And Mortality ◽  
Significant Downward Trend ◽  
Accumulation Index ◽  
One Year ◽  
The One ◽  
Statistical Indicators

Morbidity and mortality from pancreatic cancer is an urgent medical and social problem. Evaluation of statistical indicators in dynamics makes it possible to identify organizational and clinical problems in providing care to patients with malignant neoplasms of the pancreas. Medical and statistical indicators of incidence of malignant pancreatic neoplasms in St. Petersburg residents are evaluated. The assessment of medical and statistical indicators of the incidence of malignant neoplasms of the pancreas in residents of St. Petersburg. Statistical data were studied for the period from 2014 to 2019. The increase in the "rough" indicator of primary morbidity changed from 417.99 per 100 thousand population in 2014 to 505.6 in 2019. In the structure of primary cancer incidence, the indicator of active detection of pancreatic cancer glands in 2014 amounted to 3.6%, in 2019 3.8%. The proportion of patients with diagnoses confirmed morphologically increased from 48.9% to 61.4%. The proportion of patients with newly diagnosed stage IV of the disease changed from 39.5% in 2014 to 51.4% in 2019, and in patients with stage III in 2019 it was 33.3% (a decrease in comparison with 2014 15.3%). In 2019, the disease was diagnosed at stage II in 15.2% of patients. The proportion of patients with stage I in 2019 was 6.6%, this indicator in 2014 was registered at the level of 19.2%. From 2014 to 2019, the one-year mortality rate did not change and amounted to 67.9 and 67.4%, respectively (the decrease was 0.7%). Over the past 5 years, there has been no significant downward trend in the "rough" incidence and mortality rates from pancreatic cancer. However, in the dynamics, there was an increase in the number of patients registered for 5 or more years, and an increase in the accumulation index of the contingent of patients with pancreatic cancer.

scholarly journals Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question

2020 ◽  
Vol 93 (1106) ◽  
pp. 20190627
Author(s):  
Marta Scorsetti ◽  
Tiziana Comito ◽  
Davide Franceschini ◽  
Ciro Franzese ◽  
Maria Giuseppina Prete ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Overall Survival ◽  
Pancreatic Adenocarcinoma ◽  
Local Treatment ◽  
Stage Iv ◽  
Progression Free Survival ◽  
Free Survival ◽  
Number Of Patients ◽  
Clinical Considerations

Objectives: To evaluate the role of stereotactic body radiotherapy (SBRT) as a local ablative treatment (LAT) in oligometastatic pancreatic cancer. Methods: Patients affected by histologically confirmed stage IV pancreatic adenocarcinoma were included in this analysis. Endpoints are local control (LC), progression-free survival (PFS), and overall survival (OS). Results: From 2013 to 2017, a total of 41 patients were treated with SBRT on 64 metastases. Most common sites of disease were lung (29.3%) and liver (56.1%). LC at 1 and 2 years were 88.9% (95% CI 73.2–98.6) and 73.9% (95% CI 50–87.5), respectively. Median LC was 39.9 months (95% CI 23.3—not reached). PFS rates at 1 and 2 years were 21.9% (95% CI 10.8–35.4) and 10.9% (95% CI 3.4–23.4), respectively. Median PFS was 5.4 months (95%CI 3.1–11.3). OS rates at 1 and 2 years were 79.9% (95% CI 63.7–89.4) and 46.7% (95% CI 29.6–62.2). Median OS was 23 months (95%CI 14.1–31.8). Conclusions: Our results, although based on a retrospective analysis of a small number of patients, show that patients with oligometastatic pancreatic cancer may benefit from local treatment with SBRT. Larger studies are warranted to confirm these results. Advances in knowledge: Selected patients affected by oligometastatic pancreatic adenocarcinoma can benefit from local ablative approaches, like SBRT

Robot-Asssisted Laparoscopic Radical Prostatectomy (Ralp). Oncological and Functional Findings after 90 Cases

2009 ◽  
Vol 76 (2) ◽  
pp. 87-89 ◽  
Author(s):  
C. Giberti ◽  
M. Schenone ◽  
P. Cortese ◽  
F. Gallo ◽  
E Gastaldi ◽  
...  
Keyword(s):  
Disease Free Survival ◽  
Functional Results ◽  
Modern Technology ◽  
Nerve Sparing ◽  
Number Of Patients ◽  
Before And After ◽  
Disease Free Survival Rate ◽  
One Year ◽  
The One

The RALP is the most modern technology available for the treatment of intracapsular prostate cancer (CaP), which can produce a shorter learning curve and better results than the traditional techniques. Methods Between March 2005 and March 2008, 90 patients (64.3 ys, range 52–71) with intracapsular CaP underwent RALP at our institute. Before surgery the patients underwent routine examinations and filled in IIEF, IPSS and EORTC-QLQC30/PR 25 questionnaires. Patients were followed up with PSA assay, physical examination and compilation of the questionnaires. Median follow-up was 12.5 months (range 1–35 months). Results Mean operative time was 230 min. Discharge and catheter removal were at day 7.4 and 8.2, respectively, after surgery. Pathological staging reported pT2 and pT3 in 57 (63%) and 33 patients (37%), respectively. Positive surgical margins were assessed in 30 patients (33%), particularly 8.7% in pT2 tumors. The one-year biochemical disease-free survival rate was 90%. Regarding the functional results, 81 patients (90%) were perfectly continent while a mild and a moderate incontinence were reported in 7 (8%) and 2 (2%) patients, respectively. Mean IPSS score decreased from 8 to 4; among the patients who underwent bilateral nerve sparing RALP and no adjuvant therapy, 31 (70.4%) reported satisfactory sexual intercourses. Concerning postoperative quality of life, mean EORTC-QLQC30/PR 25 questionnaires scores were very similar before and after RALP. Conclusions After 90 cases of RALP the oncological and functional results are definitely promising. However, a wider number of patients and a greater follow-up are needed to confirm these data particularly as regards the functional results.

RP101 improves the efficacy of gemcitabine in treating pancreatic carcinoma

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14075-14075
Author(s):  
M. Haenel ◽  
D. Quietzsch ◽  
V. Heinemann ◽  
S. Boeck ◽  
R. M. Schmid ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Median Survival ◽  
Phase 1 ◽  
Advanced Pancreatic Cancer ◽  
Stage Iv ◽  
Underlying Disease ◽  
Fixed Dose ◽  
Survival Status ◽  
Phase 2 Study ◽  
One Year

14075 Background: (E)-5-(2-bromovinyl)-2’-deoxyuridine (BVDU, RP101), was initially tested in a phase 1 pilot study in pancreatic cancer. Patients (n=13) received gemcitabine (1000 mg/m2), cisplatin (50 mg/m2) and RP101 (500 mg/day). The median survival was 447 days and the TTP was 280 days. Ten of the 13 pts lived longer than one year, 4 nearly two years. Based on these promising results a phase 2 study was initiated to explore varying doses of RP101 used with a fixed dose of GEM. Methods: Pts with advanced pancreatic adenocarcinoma were eligible for treatment in this single arm study. 22 pts (16 stage IV and 5 stage III) received GEM 1000 mg/m2 on days 1, 8 and 15 of a 28-day schedule. RP101 treatment, at doses of 500, 625, 750, 875 or 1000 mg/day, was on the same day and for three days after chemotherapy. The mean age was 60 years and 73% of pts were males. Results: The results are based on interim data from an ongoing study and patients at the 2 highest dose groups are still being treated. All RP101 dose groups were combined for analyses, which included all enrolled pts. The data on the 6-month survival status show that 41% are alive; 23% dead; and 36% followed less than 6 months. The median survival (95% CI) is 7.1 months (5.9, not calculated) and 14/22 pts (64%) are still alive. The 6 month survival rate (95% CI) is 0.69 (0.52, 0.85). This compares very favorably with a large recent randomized trial in which pts who received GEM alone had a median survival (95%CI) of 5.9 months (5.1–6.7). PFS and TTP continue to be assessed in this ongoing trial. There appears to be a dose dependent increase in peak GEM levels as a function of the dose of RP101. To date, adverse events are consistent with those observed with GEM or the underlying disease. Conclusion: RP101 may improve treatment of advanced pancreatic cancer when used with gemcitabine. Updated data on survival, PFS, and safety will be presented based on available data. [Table: see text]

scholarly journals Esophageal cancer: analytical indicators of cancer service efficacy

2020 ◽  
Vol 55 (1) ◽  
pp. 12-15
Author(s):  
K. TOLEUTAIULУ ◽  
A. ZHYLKAYDAROVA ◽  
U. ZHUMASHEV ◽  
S. YESSENKULOVA ◽  
A. JAKIPBAYEVA ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Surgical Treatment ◽  
Early Detection ◽  
Cancer Incidence ◽  
Malignant Tumors ◽  
Stage Iv ◽  
Cancer Service ◽  
Number Of Patients ◽  
Incidence And Mortality ◽  
The Republic

Relevance: Esophageal cancer ranks eighth in the structure of malignant tumors in the Republic of Kazakhstan. According to the Kazakh Institute of Oncology and Radiology, in 2018, 1225 were primarily registered with esophageal cancer, and 825 patients died from this disease. The purpose of this study was to analyze the esophageal cancer incidence and mortality among the population of the Republic of Kazakhstan in 2009-2018 and determine the cancer service efficacy. Results: The analysis of intensive indicators of esophageal cancer incidence showed a decrease in the number of primary cases from 8.2‰ in 2009 to 6.7‰ in 2018, and the mortality – from 6.9‰ to 3.8‰. The share of early detection (Stage I-II) increased by 38.2% since 2009 to reach 52.1% in 2018. The share of stage IV esophageal cancer decreased from 7.2% in 2009 to 5.8% in 2018. One-year mortality decreased by 14.7% since 2009 to reach 41.2% in 2018, which speaks of the improvements in the timely diagnosis of esophageal cancer. The number of patients who received radical comprehensive treatment increased by 8.6% to reach 32.2% in 2018. The number of patients who received surgical treatment in 2009-2018 remained almost at the same level and amounted to 18.9 and 18.0%, respectively. However, during the years of screening for esophageal cancer, the proportion of surgical treatment increased from 26.6% to 30.4%. The ratio of incidence to mortality decreased from 91.4% to 68.8% in the study period indicating an improvement in the level of cancer service in the Republic of Kazakhstan. Conclusion: The analysis of intensive indicators of esophageal cancer incidence showed a decrease in primary incidence. The screening conducted in 2013-2016 has shown an improvement in early detection of esophageal cancer (stages I-II) and a decrease in the share of the advanced stage. The findings of this study shall serve as the basis for planning anti-cancer measures

Analysis of statistics of pancreatic cancer in Ukraine for a period of 10 years.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16721-e16721
Author(s):  
Liliia Zrielykh
Keyword(s):  
Pancreatic Cancer ◽  
Health Financing ◽  
Cancer Registries ◽  
Special Treatment ◽  
Number Of Patients ◽  
Incidence And Mortality ◽  
World Standard ◽  
Access To Medical Care ◽  
Low Coverage ◽  
Medical Examinations

e16721 Background: Pancreatic cancer (PC) is the 7th leading cause of cancer death in both sexes and 12th most common cancer worldwide. The estimated 5-year survival rate for it is nearly 5% both in developed and in developing countries. Methods: Analysis of data of National and regional cancer registries. Results: Number of new PC cases in 2003 in Ukraine was 4837 ( men – 2666, women – 2171), in 2013 – 5296 ( men – 2877, women – 2419). So the number of PC cases increased by 8,7% ( by 7,3% in men, by 10,3% in women) in 2013 in comparison to 2003. Number of deaths from PC in 2003 was 4115 (men – 2291, women – 1824), in 2013 – 4307 ( men – 2328, women – 1979). The number of PC deaths increased by 4,5% ( by 1,6% in men, by 7,8% in women). Incidence of PC in children population (age 0-17 years) in 2003 was 0, in 2013 – 4 ( men – 0, women – 4). Age-standardised incidence rate (world standard) of PC in 2003 was 5,9 ( 8,6 in men; 4,0 in women), in 2013 – 6,8 ( 9,8 in men; 4,7 in women). Age-standardised mortality rate (world standard) in 2003 was 5,0 ( men – 7,4; women – 3,4), in 2013 – 5,5 ( men – 7,9; women – 3,9). Patients diagnosed during the preventive medical examinations in 2003 were 3.8% ( men – 3,6%, women – 4,1%), in 2013 - 3.2% ( men – 3,2%, women – 3,3%). Newly diagnosed patients received the special treatment in 2003 were 27,6% (men – 28,7%, women – 26,1%), in 2013 - 26% (men – 25,5%, women – 26,6%). From among them surgical treatment only received 60.8% in 2003, 45.9% in 2013, Combined or complex scheme of treatment received 10.1% in 2003, 10.5% in 2013. The percentage of histologically verified PC in 2003 – 28,4%, in 2013 was 33,6%. Conclusions: There is a tendency of increase of incidence and mortality rates of PC in Ukraine. There have been cases of morbidity in children in 2013 compared with 2003. The number of patients revealed during preventive medical examinations remains low in 2013 and in 2003 due to low health financing, low coverage of preventive medical examinations. The number of patients who received special treatment remains low during 10 years. This is mainly due to lack of access to medical care, high cost of treatment, diagnosis of PC at an advanced stage.

Nurse-led ‘one stop’ clinic for elective tonsillectomy referrals

2007 ◽  
Vol 121 (4) ◽  
pp. 378-381 ◽  
Author(s):  
K Wu ◽  
E Walker ◽  
G Owen
Keyword(s):  
Nurse Practitioner ◽  
County Hospital ◽  
Number Of Patients ◽  
Lincoln County ◽  
One Stop ◽  
One Year ◽  
The One ◽  
Complete Process ◽  
Trained Nurse ◽  
Made In

Objectives: Balancing new referrals with limited clinic capacity is a challenge. At Lincoln County Hospital, referrals for tonsillectomy have been managed by an experienced ENT nurse practitioner, in order to deal with this problem more effectively. We reviewed tonsillectomy referrals made in a one year period to determine if surgical outcomes were satisfactory. Results were compared with figures available from the national prospective tonsillectomy audit.Methods: This was a retrospective study, assessing patients referred to the ENT department at Lincoln County Hospital. We reviewed the number of patients who had proceeded to surgery and the rate of complications.Results: One hundred and fifty-nine patients had been referred for tonsillectomy over the one year period. One hundred and forty-seven patients had been seen in clinic and 12 had not attended their clinic appointment. Following consultation with the nurse practitioner, 125 patients had proceeded to surgery. Five episodes of bleeding were recorded as complications postoperatively; giving a bleeding complication rate of 4.7 per cent, compared with a rate of 5.7 per cent from the national prospective tonsillectomy audit.Conclusion: A trained nurse practitioner can safely and effectively facilitate the complete process of managing a routine pre-operative tonsillectomy patient, from primary care referral to arranging admission for surgery.

Prodromal depression in pancreatic cancer: Retrospective evaluation on ten patients

2014 ◽  
Vol 13 (3) ◽  
pp. 801-807 ◽  
Author(s):  
Johan Sebti ◽  
Françoise Desseigne ◽  
Pierre Saltel
Keyword(s):  
Pancreatic Cancer ◽  
Depressive Episode ◽  
Major Depressive Episode ◽  
Neoplastic Disease ◽  
Major Depressive ◽  
Psychiatric Interview ◽  
Subsyndromal Depression ◽  
One Year ◽  
The One ◽  
Depressive Syndromes

AbstractObjective:Since the description by Yaskin in 1931, it has been observed that pancreatic cancer and depression are two clinical entities that share a high affinity. This observation relies on the higher incidence of depressive syndromes associated with pancreatic cancer than in any other type of digestive tumor, and on the possible occurrence of depressive symptoms several months before the diagnosis of cancer. We present here a series of cases whose screening returned positive for depression-related diagnoses in the months prior to revelation of the cancer.Method:We employed a structured psychiatric interview based on DSM–IV criteria (SCID–I). The diagnoses considered were major depressive episode, minor depressive episode, and subsyndromal depression. All subjects were free of psychiatric history.Results:Some 15 patients were initially included: 10 presented compatible criteria for a past depressive episode, 2 presented a major depressive episode, 4 met the diagnosis of minor depression, and 4 evidenced subsyndromal depression over the one-year period prior to cancer diagnosis.Significance of results:This series of cases is consistent with previous work on the subject that suggested an increased vulnerability to depressive events in the premorbid phase of pancreatic cancer. If the possibility of depressive syndromes constituting the early stages of neoplastic disease is a common idea, it is still impossible to determine the natural history of these two disorders and therefore their causal linkage.

scholarly journals ONCOLOGICAL CARE FOR THE PATIENTS WITH HEPATOCELLULAR CARCINOMA IN SVERDLOVSK REGION

2020 ◽  
Vol 66 (4) ◽  
pp. 364-369
Author(s):  
Vladislav Petkau ◽  
V. Breder ◽  
E. Bessonova ◽  
A. Tarkhanov
Keyword(s):  
Current Issue ◽  
Annual Number ◽  
Post Mortem ◽  
Virus Hepatitis ◽  
Standardized Incidence Ratio ◽  
The People ◽  
Number Of Patients ◽  
One Year ◽  
The One ◽  
Regular Alcohol Consumption

HCC epidemiologic data in Sverdlovsk region are presented in current issue. 1293 of new cases of HCC were diagnosed since 2015 till 2019. The incidence rate of HCC in 2019 was 6,53 cases per 100000 people and standardized incidence ratio was 3,48 per 100000 people. The maximum of new cases was among the people older than 70 years. HCC developed in cirrhotic liver in 70,2% of cases. The main risk factors were virus hepatitis (49,6%), regular alcohol consumption (23%) and obesity (9,9%). The post-mortem diagnosis exceeds 40% of cases. The one-year mortality was 72-73%. The number of patients with HCC sent to the regional oncology dispensary increased in the last 5 years in 5 times. There were 124 of such patients in 2019. The majority has HCC at BCLC D stage (56,5%). Only 16,7% of patients received specialized treatment. The introduction of multidisciplinary team led to a doubling of annual number of treated patients with HCC.

scholarly journals LEVONORGESTREL INTRAUTERINE DEVICE VERSUS MEDROXYPROGESTERONE ACETATE IN TREATMENT OF SYMPTOMATIC UTERINE FIBROIDS

2018 ◽  
Vol 6 (7) ◽  
pp. 341-347
Author(s):  
Uğurkan Erkayıran ◽  
Bülent Köstü ◽  
Alev Özer ◽  
Abdullah Tok ◽  
Selim Karaküçük
Keyword(s):  
Pelvic Pain ◽  
Medroxyprogesterone Acetate ◽  
Intrauterine Device ◽  
Uterine Fibroids ◽  
Abnormal Uterine Bleeding ◽  
Good Choice ◽  
Uterine Bleeding ◽  
Number Of Patients ◽  
One Year ◽  
The One

Background: Medroxyprogesterone acetate (MPA) and levonorgestrel intrauterine device (LNG-IUD) are two drugs used to treat abnormal uterine bleeding in women with myoma. We organized this study to compare the effectiveness of these two treatments. Methods: This was a retrospective one-year-long cohort study of 95 women with uterine leimyoma. Fifty three women who had received LNG-IUD formed the LNG-IUD group while 42 women who received regular intramuscular injections of 150 mg MPA at every 3 months for one-year period made up the MPA group. Both groups were compared in aspect of demographic, clinical and biochemical characteristics. Results: At the end of one year, the LNG-IUD group had significantly smaller fibroid size, lower visual analogus scale score for pelvic pain, for dysmenorrhea and dyspareunia than the MPA group. There were a significant reduction in the number of patients with menorrhagia and a significant increase in serum hemoglobine levels both in  LNG-IUD and MPA groups at the end of the one-year long study period. Conclusions: LNG-IUD appears as a good choice for the reduction in fibroid size and associated pelvic pain.

scholarly journals The dynamics of the incidence of breast cancer in the Moscow region (2011–2018)

2020 ◽  
pp. 166-173
Author(s):  
L. M. Kogoniya ◽  
V. I. Astashov ◽  
S. N. Minakov
Keyword(s):  
Breast Cancer ◽  
Medical Care ◽  
Clinical Symptoms ◽  
Medical Center ◽  
Mortality Rates ◽  
Diagnostic Methods ◽  
Moscow Region ◽  
Malignant Neoplasms ◽  
Number Of Patients ◽  
Incidence And Mortality

Introduction. Breast cancer is a serious medical and social challenge and the statistics around the world look daunting.Relevance. The incidence of breast cancer is increasing in most countries and this may be due to a number of reasons. First of all, it should be noted the improvement of diagnostic methods, in particular, mass mammographic screening, which allows detecting neoplasms at early stages, before the onset of clinical symptoms. As for mortality rates, in recent years, world statistics show a downward trend in rates.Goal. To analyze the incidence and mortality rates of breast cancer (BC) in the Moscow Region (MO) for the period from 2011 to 2018. The study of indicators in one of the regions of Russia – MO – is of great importance for determining and predicting the true needs of the population in specialized medical care.The purpose of the study was to analyze the incidence of breast cancer (breast cancer) in the Moscow Region (MO) for a period of time from 2011 to 2018.Materials and methods. Some data of the territorial cancer registry of the Ministry of Defense of the Russian Federation on the diagnosis and treatment of patients with breast cancer were used, which will make it possible to determine the needs of this cohort of patients in specialized care.Results. From 2011 to 2018, 26755 new cases of breast cancer were diagnosed in the Moscow Region. The analysis of the comparative stratification in breast cancer in the medical district made it possible to obtain statistically significant differences indicating an increase in the incidence in the period from 2015–2018 in comparison with the period of 2011–2014. The presented data also indicate a trend towards a decrease in the one-year mortality rate over 8 years: from 6.33% in 2011 to 5.32% in 2018. For the period from 2011 to 2018 (8 years) there is an increase in the number of patients with breast cancer who have been in the medical center under dispensary supervision for 5 years or more.Conclusions. Analysis of the data obtained on the indicators of morbidity and mortality from malignant neoplasms is of great importance for determining the needs of the population in specialized medical care.

Sign in / Sign up

Export Citation Format

Share Document